Introduction
Materials and methods
Clinical samples
Gene expression analysis
Somatic mutation analysis
Matched breast primary-brain metastasis pairs | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Case ID# | Site | ER - PgR- HER 1-2-3-4 |
EGFR
|
NRAS
|
PIK3CA
| |||||||
Mutation | MAP | Mutation | MAP | Mutation | MAP | |||||||
1
|
brain
| ER-, PgR-, HER1-, HER2+, HER3-, HER4- | ||||||||||
breast
| ER-, PgR-, HER1-, HER2+, HER3-, HER4- | |||||||||||
2
|
brain
| ER-, PgR-, HER1-, HER2-, HER3+, HER4- | Q61RO, H, I, S
| 39.50% | ||||||||
breast
| ER-, PgR-, HER1-, HER2-, HER3+, HER4- | Q61RO, H, I, S
| 38.30% | |||||||||
4
|
brain
| ER-, PgR+, HER1+, HER2-, HER3-, HER4- | ||||||||||
breast
| ER-, PgR+, HER1+, HER2-, HER3-, HER4- | |||||||||||
6
|
brain
| ER-, PgR+, HER1+, HER2-, HER3-, HER4- | ||||||||||
breast
| ER-, PgR+, HER1+, HER2-, HER3-, HER4- | |||||||||||
7
|
brain
| ER-, PgR-, HER1+, HER2-, HER3-, HER4- | Q61RI, S
| 34.4% | ||||||||
breast
| ER-, PgR-, HER1+, HER2-, HER3-, HER4- | Q61RI, S
| 34.1% | |||||||||
8
|
brain
| ER-, PgR-, HER1-, HER2+, HER3+, HER4- | ||||||||||
breast
| ER-, PgR-, HER1-, HER2+, HER3-, HER4- | |||||||||||
9
|
brain
| ER-, PgR-, HER1-, HER2+, HER3-, HER4- | H1047RS
| 79.50% | ||||||||
breast
| ER-, PgR-, HER1-, HER2+, HER3-, HER4- | H1047RS
| 79.50% | |||||||||
10
|
brain
| ER-, PgR-, HER1+, HER2-, HER3+, HER4- | E545KH, NVP
| 23.40% | ||||||||
breast
| ER-, PgR-, HER1+, HER2-, HER3-, HER4- | E545KH, NVP
| 18.20% | |||||||||
11
|
brain
| ER-, PgR-, HER1-, HER2+, HER3-, HER4+ | ||||||||||
breast
| ER-, PgR-, HER1-, HER2+, HER3-, HER4+ | |||||||||||
12
|
brain
| ER-, PgR+, HER1-, HER2-, HER3+, HER4- | ||||||||||
breast
| ER-, PgR+, HER1-, HER2-, HER3+, HER4- | |||||||||||
13
|
brain
| ER-, PgR-, HER1+, HER2-, HER3-, HER4- | ||||||||||
breast
| ER-, PgR-, HER1+, HER2-, HER3-, HER4- | N771_P772>SVDNR | 12.10% | |||||||||
14
|
brain
| ER-, PgR-, HER1+, HER2-, HER3-, HER4- | ||||||||||
breast
| ER-, PgR-, HER1+, HER2-, HER3-, HER4- | |||||||||||
Unmatched brain metastases from primary lung, colon, melanoma and kidney tumours
| ||||||||||||
Case ID#
|
Site
|
ER - PgR- HER 1-2-3-4
|
EGFR
|
HRAS
|
KRAS
|
NRAS
|
PIK3CA
| |||||
Mutation
|
MAP
|
Mutation
|
MAP
|
Mutation
|
MAP
|
Mutation
|
MAP
|
Mutation
|
MAP
| |||
D2
|
melanoma
| n.a. | E545KH, I, Y
| 30.80% | ||||||||
D3
|
colon
| n.a. | G12CS
| 38.90% | ||||||||
D4
|
lung
| n.a. | E746_A750delA
| 21.00% | ||||||||
D5
|
lung
| n.a. | ||||||||||
D6
|
lung
| n.a. | E746_A750delA, NVI
| 14.40% | G13S
I
| 17.30% | G12CI;S
| 35.70% | ||||
D7
|
lung
| n.a. | G12C
O;I
| 9.70% | ||||||||
D8
|
lung
| n.a. | G12CS
| 39.90% | ||||||||
D9
|
lung
| n.a. | E545KH
| 13.30% | ||||||||
D10
|
kidney
| n.a. | E746_A750delA, I
| 9.10% | G12C
I, S
| 35.20% |